Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Evaxion Biotech A/S (EVAX)

0.859   -0.001 (-0.12%) 10-02 16:00
Open: 0.88 Pre. Close: 0.86
High: 0.88 Low: 0.8151
Volume: 63,719 Market Cap: 24(M)

Technical analysis

as of: 2023-10-02 4:49:56 PM
Short-term rate:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Mid-term rate:       
Target: Six months: 1.07     One year: 1.25
Support: Support1: 0.64    Support2: 0.46
Resistance: Resistance1: 0.92    Resistance2: 1.07
Pivot: 0.74
Moving Average: MA(5): 0.83     MA(20): 0.74
MA(100): 1.16     MA(250): 1.54
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 83.8     %D(3): 82.3
RSI: RSI(14): 53.5
52-week: High: 3.09  Low: 0.46
Average Vol(K): 3-Month: 122 (K)  10-Days: 397 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ EVAX ] has closed below upper band by 21.1%. Bollinger Bands are 24.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.88 - 0.88 0.88 - 0.89
Low: 0.81 - 0.81 0.81 - 0.81
Close: 0.85 - 0.86 0.86 - 0.86

Company Description

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.

Headline News

Thu, 21 Sep 2023
Evaxion (EVAX) Up on Partnership With Afrigen for Gonorrhea Jab - Nasdaq

Wed, 20 Sep 2023
Other news to note for Sept. 20, 2023 - BioWorld Online

Wed, 20 Sep 2023
Evaxion Partners With Pharmaceutical Company Afrigen Biologics ... - GlobeNewswire

Mon, 18 Sep 2023
Evaxion expands preclinical bacterial vaccine pipeline in ... - BioSpace

Mon, 11 Sep 2023
Revolutionizing Vaccine Discovery: New Data Validates Evaxion AI ... - BioSpace

Tue, 29 Aug 2023
Evaxion announces Executive Management Changes to strengthen ... - GlobeNewswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 28 (M)
Shares Float 19 (M)
% Held by Insiders 32.7 (%)
% Held by Institutions 1.1 (%)
Shares Short 175 (K)
Shares Short P.Month 332 (K)

Stock Financials

EPS -1.55
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.09
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -60.8
Return on Equity (ttm) -216.4
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.88
Qtrly Earnings Growth 0
Operating Cash Flow -24 (M)
Levered Free Cash Flow -16 (M)

Stock Valuations

PE Ratio -0.56
PEG Ratio 0
Price to Book value 9.54
Price to Sales 0
Price to Cash Flow -1.01

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.